CANCER TARGETED TECH LLC has a total of 26 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2007. It filed its patents most often in EPO (European Patent Office), Australia and China. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and environmental technology are FRIEDHEIM ERNST A H, VUAB PHARMA A S and DRUG INNOVATION & DESIGN INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 5 | |
#2 | Australia | 4 | |
#3 | China | 4 | |
#4 | United States | 3 | |
#5 | WIPO (World Intellectual Property Organization) | 3 | |
#6 | Brazil | 2 | |
#7 | Canada | 2 | |
#8 | Mexico | 2 | |
#9 | Hungary | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Berkman Clifford | 21 |
#2 | Choy Cindy | 11 |
#3 | Stekhova Svetlana A | 5 |
#4 | Clifford Berkman | 4 |
#5 | Cindy Choy | 4 |
#6 | Wang Xiaobing | 3 |
#7 | Langton-Webster Bea | 2 |
#8 | Langton Webster Bea | 1 |
#9 | Stekhova Svetlana | 1 |
#10 | Berkman Cliff | 1 |
Publication | Filing date | Title |
---|---|---|
WO2021046233A1 | Chelate-containing psma inhibitors | |
MX2019005742A | Albumin-binding psma inhibitors. | |
AU2017311510A1 | Chelated PSMA inhibitors | |
EP2721039A1 | Chelated psma inhibitors |